We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA released two draft guidances on Thursday outlining the agency’s latest thinking on assessments of risk evaluation and mitigation strategy (REMS) programs.